Literature DB >> 238862

Rates of onset and offset of action of narcotic analgesics in isolated preparations.

H W Kosterlitz, F M Leslie, A A Waterfield.   

Abstract

In isolated preparations of the myenteric plexus--longitudinal muscle of the guinea-pig ileum and the mouse vas deferens, the rates of onset and offset of action of narcotic analgesics are inversely related to lipid solubility; this effect is probably due to drug binding at secondary lipid-rich binding sites. These findings are in contrast to observations in vivo by A. Herz and his colleagues, who showed that the rates of onset of action and of recovery are directly related to lipid solubility because of the presence of lipid-rich barriers. In view of the opposite effects, an optimum may be expected when a drug has a degree of lipid solubility which ensures rapid penetration of the blood--brain barrier without seriously slowing down of receptor association and dissociation. From the interaction of rapidly acting quaternary antagonists, e.g. N-methylnalorphinium, with slowly acting agonists, e.g. methadone, it is concluded that at least a part of the receptor site is on the surface of the cell membrane, and the possibility of an allosteric agonist--antagonist interaction is considered.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 238862     DOI: 10.1016/0014-2999(75)90317-9

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  8 in total

1.  Opiate agonist action of antidiarrheal agents in vitro and in vivo--findings in support for selective action.

Authors:  M Wüster; A Herz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1978 Jan-Feb       Impact factor: 3.000

2.  The binding spectrum of narcotic analgesic drugs with different agonist and antagonist properties.

Authors:  J Magnan; S J Paterson; A Tavani; H W Kosterlitz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-06       Impact factor: 3.000

3.  Depression by morphine of excitatory junction potentials in the vas deferens of the mouse.

Authors:  G Henderson; R A North
Journal:  Br J Pharmacol       Date:  1976-07       Impact factor: 8.739

Review 4.  Buprenorphine: a review of its pharmacological properties and therapeutic efficacy.

Authors:  R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1979-02       Impact factor: 9.546

5.  Mechanism-based pharmacokinetic-pharmacodynamic modelling of the reversal of buprenorphine-induced respiratory depression by naloxone : a study in healthy volunteers.

Authors:  Ashraf Yassen; Erik Olofsen; Eveline van Dorp; Elise Sarton; Luc Teppema; Meindert Danhof; Albert Dahan
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

6.  Agonist and antagonist properties of buprenorphine, a new antinociceptive agent.

Authors:  A Cowan; J W Lewis; I R Macfarlane
Journal:  Br J Pharmacol       Date:  1977-08       Impact factor: 8.739

7.  Identification of an additional supraspinal component to the analgesic mechanism of action of buprenorphine.

Authors:  Zhe Ding; Robert B Raffa
Journal:  Br J Pharmacol       Date:  2009-04-30       Impact factor: 8.739

8.  A naloxone-steroid hybrid azine with selective and long-acting opioid antagonism at delta receptors in vitro.

Authors:  A Koman; V M Kolb; L Terenius
Journal:  Pharm Res       Date:  1987-04       Impact factor: 4.200

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.